万泰生物(603392.SH)上半年净利大跌84.70%至2.60亿元二价及九价宫颈癌疫苗收入回落

智通财经08-22

智通财经APP讯，万泰生物(603392.SH)发布2024年半年度报告，报告期内公司实现营业收入13.66亿元，同比减少67.19%;归属于上市公司股东的净利润2.60亿元，同比减少84.70%;归属于上市公司股东扣除非经常性损益净利润6352.06万元，同比减少96.09%;基本每股收益0.21元/股。营业收入下降，主要由于公司二价宫颈癌疫苗持续受九价宫颈癌疫苗扩龄影响以及市场竞争、降库存等...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461667583?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-22 15:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461667583","market":"sh","top_or_hot":-1,"title":"万泰生物(603392.SH)上半年净利大跌84.70%至2.60亿元 二价及九价宫颈癌疫苗收入回落","media":"智通财经","content":"<div>\n<p>智通财经APP讯，万泰生物(603392.SH)发布2024年半年度报告，报告期内公司实现营业收入13.66亿元，同比减少67.19%;归属于上市公司股东的净利润2.60亿元，同比减少84.70%;归属于上市公司股东扣除非经常性损益净利润6352.06万元，同比减少96.09%;基本每股收益0.21元/股。营业收入下降，主要由于公司二价宫颈癌疫苗持续受九价宫颈癌疫苗扩龄影响以及市场竞争、降库存等...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1168337.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>万泰生物(603392.SH)上半年净利大跌84.70%至2.60亿元 二价及九价宫颈癌疫苗收入回落</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n万泰生物(603392.SH)上半年净利大跌84.70%至2.60亿元 二价及九价宫颈癌疫苗收入回落\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 15:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1168337.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，万泰生物(603392.SH)发布2024年半年度报告，报告期内公司实现营业收入13.66亿元，同比减少67.19%;归属于上市公司股东的净利润2.60亿元，同比减少84.70%;归属于上市公司股东扣除非经常性损益净利润6352.06万元，同比减少96.09%;基本每股收益0.21元/股。营业收入下降，主要由于公司二价宫颈癌疫苗持续受九价宫颈癌疫苗扩龄影响以及市场竞争、降库存等...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1168337.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09633","symbol_name":"农夫山泉","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1168337.html","article_id":"2461667583","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461667583","pubTimestamp":1724313070,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，万泰生物 发布2024年半年度报告，报告期内公司实现营业收入13.66亿元，同比减少67.19%;归属于上市公司股东的净利润2.60亿元，同比减少84.70%;归属于上市公司股东扣除非经常性损益净利润6352.06万元，同比减少96.09%;基本每股收益0.21元/股。营业收入下降，主要由于公司二价宫颈癌疫苗持续受九价宫颈癌疫苗扩龄影响以及市场竞争、降库存等因素影响，销售收入较去年同期回落。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","603392":"万泰生物","09633":"农夫山泉","LU1981816686.USD":"EASTSPRING INV ASIAN MULTI FACTOR EQUITY \"A\" (USD) ACC","BK1200":"软饮料","BK0239":"医药制造","BK1589":"北水核心资产"},"translate_title":"Wantai Biotech (603392. SH) 's net profit in the first half of the year fell 84.70% to 260 million yuan, and revenue from bivalent and nine-valent cervical cancer vaccines fell","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"603392":1,"09633":1},"content_text":"智通财经APP讯，万泰生物(603392.SH)发布2024年半年度报告，报告期内公司实现营业收入13.66亿元，同比减少67.19%;归属于上市公司股东的净利润2.60亿元，同比减少84.70%;归属于上市公司股东扣除非经常性损益净利润6352.06万元，同比减少96.09%;基本每股收益0.21元/股。营业收入下降，主要由于公司二价宫颈癌疫苗持续受九价宫颈癌疫苗扩龄影响以及市场竞争、降库存等因素影响，销售收入较去年同期回落。截至本报告披露日，公司二价HPV疫苗已获得中国(不包括港澳台)、摩洛哥、尼泊尔、泰国、刚果(金)、柬埔寨、埃塞俄比亚、哈萨克斯坦、肯尼亚、布基纳法索、安哥拉、马里、缅甸、印度尼西亚、加纳、埃及、马达加斯加、尼日尔、危地马拉的市场准入，并已纳入泰国、尼加拉瓜、安哥拉、尼泊尔四国的扩大免疫规划。公司九价HPV疫苗III期临床试验和产业化放大进展顺利，已按计划完成III期临床主试验V8访视的标本检测，揭盲主要结果符合预期;V9访视正在进行中;与佳达修9头对头免疫原性比较研究结果显示两者相当;小年龄组桥接临床已完成;男性群体的临床试验正在规划中;商业化的生产条件已具备，上市申报正按计划推进中。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461667583"}

万泰生物(603392.SH)上半年净利大跌84.70%至2.60亿元 二价及九价宫颈癌疫苗收入回落

精彩评论

万泰生物(603392.SH)上半年净利大跌84.70%至2.60亿元二价及九价宫颈癌疫苗收入回落